PPARα/γ agonists like saroglitazar improve insulin resistance, suppress SREBP1c-mediated lipogenesis, and attenuate oxidative stress via nuclear factor erythroid 2 like 2 (NRF2) activation, demonstrating efficacy in preclinical steatosis and fibrosis models [63]. The gene discussed is PPARA; the disease is steatosis.